Bimekizumab well tolerated, efficacious over three years in axial spondyloarthritis

3 months ago 10
For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is good tolerated implicit 3 years, according to a survey published successful the June contented of the Journal of Rheumatology.
Read Entire Article